Telehealth providers offering compounded tirzepatide represented the largest volume prescriber channel for weight loss GLP-1 therapy in the United States during 20232024, with an estimated 400,000600,000 active patients receiving compounded semaglutide or tirzepatide through online platforms
Tissue-Specific Distribution: The selectivity is further enhanced by the tissue distribution of beta-3 adrenergic receptors
[Google Scholar] 148.Lin L, Xu X, Yu Y, Ye H, He X, Chen S, et al
Your Medicare Part D plan is already paying for your GLP-1 medication
The lack of standardisation in supplement manufacturing means that the actual content and potency of GOLO's ingredients may vary between batches, making it difficult to predict potential interactions